Background:
The Diagnostic Molecular Pathology Division will replace the current CYP2C19 assay that is performed on the Spartan Rx platform to a TaqMan-based platform. This change is necessary as the Spartan Rx assay is no longer being manufactured.
Methodology and reporting:
TaqMan-mediated PCR amplification is done on DNA extracted from peripheral blood. This test is designed to identify *2, *3, and *17 alleles. Thus, a *1 genotype indicates the absence of *2, *3, and *17 alleles only and does not preclude the existence other 2C19 allelic variants that may alter activity of the enzyme.
An interpretive report will be provided.
Effective date: Sept. 17, 2021
Specimen requirements:
Collect: 4.0 mL of blood in in EDTA tube (lavender or pink top) preferred. ACD (light yellow top) or Sodium Citrate (blue top) also acceptable.
Minimum volume: 0.5 mL whole blood
Test code: 2C19
CPT code: 81225
Turnaround time (TAT):
STAT: N/A
Routine: 3-7 days
Set up days: Twice a week
Stability:
Ambient: 24 hours
Refrigerated: 7 days from collection date
Frozen: Unacceptable
Rejection criteria:
Specimens that exceed stated stability, unlabeled/mislabeled specimens, specimens drawn in incorrect collection tubes.
A summary of all tests offered by our laboratory services can be found here:
http://www.pathology.uci.edu/services/index.asp
Sincerely,
Jeff Chan, MD, PhD
Director
Division of Diagnostic Molecular Pathology
Edwin S. Monuki, MD, PhD
Chair
Department of Pathology & Laboratory Medicine
|
